PFIZER received revenue of $ 3.5 billion from Corona virus sales, and this revenue represents a quarter of the company's revenues during the first quarter of 2021.
According to Arab Net revenue has exceeded expectations of analysts of $ 3.3 billion.
Pfizer revenue was $ 14.6 billion during the first quarter, exceeding expectations of $ 13.5 billion.
The company has raised its forecast for Kovid 19 sales during the current year by 70% to 26 billion dollars, with increased demand for vaccines and expectations for the approval of US authorities to use the vaccine widely during the current month.
In contrast, Astrazenika has achieved revenues worth $ 275 million from the COVID-19 non-profit vaccine in the first quarter, while cancer sales and growth in emerging market have helped the drug company overcome profit and sales expectations.
Astrazeneca recorded revenues of $ 7.3 billion, with the exception of the contribution of the vaccine developed with Oxford University, up 15% year-on-year and higher than $ 7 billion.
The basic profits of the share rose 55% to $ 1.63, surpassing an analysts analysts of $ 1.48. The profit before taxes was about $ 1.6 billion.
But the costs related to vaccine production have exceeded revenues in the first quarter, resulting in a negative impact and loss after taxes of $ 40 million.
That was the first time that the company reveals sales figures one of the world's leading vaccines, which has been blowed because of fears of links between him and very rare blood clots, and entered the company in a legal battle with the EU on lack of delivery.
